माल्टा - अंग्रेज़ी - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - pravastatin sodium - tablet - pravastatin sodium 20 mg - lipid modifying agents

माल्टा - अंग्रेज़ी - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - pravastatin sodium - tablet - pravastatin sodium 40 mg - lipid modifying agents

इसराइल - अंग्रेज़ी - Ministry of Health

teva israel ltd - pravastatin sodium - tablets - pravastatin sodium 20 mg - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infarction: in patients with previous myocardial infarction and normal cholesterol levels pravastatin is indicated to: - reduce the risk of recurrent myocardial infarction. - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk of stroke and transient ischemic attack (tia). *hypercholesterolemia and mixed dyslipidemia: pravastatin is indicated as an adjunct to diet to reduce elevated total-c ldl-c and tg levels in patients with primary hypercholesterolemia and mixed dyslipidemia (fredrickson type iia and iib).

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - pravastatin sodium - film-coated tablet - 10 milligram(s) - hmg coa reductase inhibitors; pravastatin

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - pravastatin sodium - film-coated tablet - 20 milligram(s) - hmg coa reductase inhibitors; pravastatin

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - pravastatin sodium - film-coated tablet - 40 milligram(s) - hmg coa reductase inhibitors; pravastatin

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - pravastatin sodium - tablet - 10 milligram(s) - hmg coa reductase inhibitors; pravastatin

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - pravastatin sodium - tablet - 40 milligram(s) - hmg coa reductase inhibitors; pravastatin

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - pravastatin sodium - tablet - 20 milligram(s) - hmg coa reductase inhibitors; pravastatin

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

norton waterford - pravastatin sodium - tablet - 10 milligram(s) - hmg coa reductase inhibitors; pravastatin